Engineered Nanoformulation for Immune-modulation in Cancer
用于癌症免疫调节的工程纳米制剂
基本信息
- 批准号:10719487
- 负责人:
- 金额:$ 54.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-15 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsAntigensAntineoplastic AgentsAntitumor ResponseApoptoticBinding ProteinsBinding SitesBreast Cancer CellCTLA4 geneCancer BiologyCancer ModelCancer PatientCancer cell lineCell Cycle ArrestCell DeathCell ProliferationCell physiologyCellsCisplatinClinicalDataDendrimersDevelopmentDisease ProgressionDrug resistanceEmbryoEngineeringExhibitsGene DeliveryGeneticGrowthHumanImmuneImmune checkpoint inhibitorImmune responseImmunoglobulinsImmunologyImmunotherapyIn VitroInvadedLaboratoriesLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMediatingMessenger RNAMicrometastasisModelingMolecularMolecular TargetMucinsMusMutagensNeoplasm MetastasisOncoproteinsPathologyPathway interactionsPromoter RegionsProtein FamilyProteinsRadiation therapyRadiosensitizationRecurrent diseaseReportingResearch PersonnelResistanceSignal TransductionSmall Interfering RNASurvival RateT cell responseT-LymphocyteTNFSF10 geneTestingTherapeuticTissuesTreatment FailureTreatment outcomeVisionanti-PD-L1anti-PD-L1 therapyanti-canceranticancer activitycancer cellcancer immunotherapycancer infiltrating T cellscancer therapycell motilitychemotherapyclinical translationeffective therapyefficacy studyimmune checkpointimmunoregulationin vivoinhibitorinnovationlipid nanoparticlelung cancer cellmRNA Expressionmembermolecular targeted therapiesmultidisciplinarynanoengineeringnanoformulationnanoparticlenanotherapyneoplastic cellnovelnovel therapeutic interventionnovel therapeuticsoverexpressionpatient subsetspharmacologicpointed proteinpreclinical studyprogrammed cell death ligand 1programmed cell death protein 1protein expressionsiRNA deliverystatisticstargeted cancer therapytargeted treatmenttumortumor eradicationtumor growthtumor heterogeneity
项目摘要
Expression of immune check point (ICP) molecules on tumor cells and the host immune
cells, especially T-cells present in the tumor milieu, negatively impact the cancer treatment
outcome resulting in inefficient tumor eradication. Data also exist showing chemo- and radio-
therapy induce ICP proteins on tumor cells and thereby contributing to inactivation of tumor
infiltrating T-cells, resulting in the inability to host a robust antitumor response and culminating in
treatment failure, and disease recurrence. Hence, understanding how a cancer drug impacts
ICP will lead to development of new therapeutic strategies that can circumvent ICP-mediated
treatment failure. One such approach is to incorporate immune check point inhibitors (ICPi)
which can rekindle T-cell response and enhance the efficacy of anticancer drugs.
Studies from the PI's laboratory and others have demonstrated genetic and pharmacologic
inhibition of the human antigen R (HuR), an mRNA-binding protein that is overexpressed in
human cancer cells, results in growth inhibition, reduction in metastasis, and in increased
animal survival. While these findings support advancing HuR-targeted therapy for clinical
translation, the PI's lab has recently made a serendipitous discovery showing siRNA-
mediated silencing of HuR using a lipid-based nanoparticle (HuR-NP) induced programmed
death-ligand (PD-L)1 expression in lung cancer cells. PD-L1 is one among several ICP proteins
which when expressed by tumor cells suppress T-cell function. HuR-NP markedly induced PD-
L1 mRNA and protein expression in human lung cancer cell lines. Molecular studies showed
HuR binding site in the promoter region of PD-L1. Finally, a negative correlation between HuR
and PD-L1 expression was observed in human lung cancer tissues. To our knowledge, apart
from our own observation reported herein, there are no prior reports demonstrating the ability of
HuR to regulate PD-L1 and testing of HuR-nanotherapy with PD-L1 immunotherapy for cancer.
On the basis of our novel findings, we posit that combining HuR-nanotherapy with PD-L1
immunotherapy will demonstrate superior anticancer efficacy by eliciting strong immune
response, and reducing disease recurrence. We will test our hypothesis with three aims: Aim 1.
Determine the therapeutic benefit of LNP targeting HuR in combination with anti-PD-L1 therapy
in vitro. Aim 2. Demonstrate LNP targeted HuR treatment in combination with PD-L1
immunotherapy in in vivo using lung tumor models elicits immune response and enhanced
antitumor activity. Aim 3. Investigate the molecular mechanism by which LNP targeting HuR
modulates PD-L1 expression in lung cancer cells.
免疫检查点分子在肿瘤细胞上的表达与宿主免疫
细胞,特别是存在于肿瘤环境中的T细胞,对癌症治疗产生负面影响
结果导致低效的肿瘤根除。也有数据显示化疗和放射治疗-
治疗诱导肿瘤细胞上的ICP蛋白,从而导致肿瘤失活
渗透T细胞,导致无法产生强大的抗肿瘤反应,最终导致
治疗失败,疾病复发。因此,了解抗癌药物是如何影响
肝内胆汁淤积症将导致新的治疗策略的发展,可以绕过肝内胆汁淤积症的中介
治疗失败。其中一种方法是加入免疫检查点抑制剂(Icpi)。
可以重新激发T细胞反应,增强抗癌药物的疗效。
来自PI实验室和其他实验室的研究表明,遗传和药理学
抑制人类抗原R(HUR),这是一种过表达的mRNA结合蛋白
人类癌细胞,导致生长抑制、转移减少和增加
动物的生存。虽然这些发现支持在临床上推进HUR靶向治疗
翻译过来,PI的实验室最近偶然发现了siRNA-
利用脂基纳米粒(HUR-NP)诱导的程序化沉默HUR
死亡配体(PD-L)1在肺癌细胞中的表达PD-L1是几种ICP蛋白中的一种
当被肿瘤细胞表达时,会抑制T细胞的功能。HUR-NP可明显诱导PD-
L1基因在人肺癌细胞系中的表达分子研究表明
HUR结合位点位于PD-L1启动子区域。最后,HUR之间的负相关
人肺癌组织中可见PD-L1的表达。据我们所知,除了
从我们在此报告的观察来看,没有先前的报告表明
HUR调节PD-L1和检测HUR纳米疗法与PD-L1免疫疗法对癌症的治疗。
根据我们的新发现,我们假设将Hur纳米疗法与PD-L1相结合
免疫疗法将通过激发强大的免疫来展示优越的抗癌效果
反应,并减少疾病复发。我们将用三个目标来检验我们的假设:目标1。
确定靶向HUR的LNP联合抗PD-L1治疗的疗效
在试管中。目的2.展示LNP靶向HUR联合PD-L1治疗
利用肺肿瘤模型进行体内免疫治疗可引起免疫反应和增强
抗肿瘤活性。目的3.探讨LNP靶向HUR的分子机制
调节肺癌细胞中PD-L1的表达。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rajagopal Ramesh其他文献
Rajagopal Ramesh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rajagopal Ramesh', 18)}}的其他基金
ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope
ShEEP 请求 CytoViva 3D 暗场高光谱显微镜
- 批准号:
9906462 - 财政年份:2019
- 资助金额:
$ 54.31万 - 项目类别:
An improved IL-24 gene-based therapeutic for cancer
改进的基于 IL-24 基因的癌症疗法
- 批准号:
10326352 - 财政年份:2019
- 资助金额:
$ 54.31万 - 项目类别:
An improved IL-24 gene-based therapeutic for cancer
改进的基于 IL-24 基因的癌症疗法
- 批准号:
10544003 - 财政年份:2019
- 资助金额:
$ 54.31万 - 项目类别:
Cancer Research Training and Education Coordination
癌症研究培训和教育协调
- 批准号:
10627028 - 财政年份:2018
- 资助金额:
$ 54.31万 - 项目类别:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
铂类药物对蛋白酶体和 SQSTM1_P62 复合物的分子影响_耐药范式转变
- 批准号:
10051382 - 财政年份:2017
- 资助金额:
$ 54.31万 - 项目类别:
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance
铂类药物对蛋白酶体和 SQSTM1_P62 复合物的分子影响_耐药范式转变
- 批准号:
9478535 - 财政年份:2017
- 资助金额:
$ 54.31万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 54.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists